Pricing Reports

NICE INSIGHT REPORT

Antibody-Drug Conjugate, ADC: 2024 Market Insight, CDMO Pricing and Competitor Benchmarking

Coming September 2024
  • 2024 CDMO pricing data for competitive benchmarking
  • Primary analysis of the clinical trial landscape, including payload types and top sponsors
  • ADC manufacturing process and areas of innovation
  • 46 company profiles for a comprehensive CDMO landscape
  • Projections on one of the most anticipated markets
Learn More
Antibody-Drug Conjugate, ADC

150 pages of primary market research to support your sales team and inform your business strategy, including an exclusive survey of linker technology and payload design, as well as insights into current clinical trials and SME/investor forecasts.

Key market insights for innovators, CDMOs and investors in the Antibody–Drug Conjugate industry.

Request a Sample

The market trends that decision makers need to know

Our complete Market Analysis uses scientific insights from PhDs and researchers to provide an exhaustive overview of the ADC industry. From the emergence of ADCs as cancer treatments to how big pharma has penetrated ADC, stay ahead of market trends with our report.

 

Exclusive pricing data to benchmark against peers

Keep your sales team ahead of the curve by using our primary data for an accurate pricing comparison. Our Market Analysis provides a manufacturing process and strategic pricing study designed to give CDMOs a competitive edge.

You Might Be Interested In

Active Pharmaceutical Ingredients, API

A comprehensive market analysis with 110 major company profiles and detailed CDMO pricing information.

Published February 2024

LEARN MORE
Mammalian Cell Culture, Biologics

Comprehensive analysis of mammalian cell culture CDMOs, including price benchmarking, market trends, and over 80 company profiles.

Published June 2024

LEARN MORE